Issues in transgender dermatology: A systematic review of the literature

Considerations for the Use of Minimally Invasive Aesthetic Procedures for Facial Remodeling in Transgender Individuals

“…9,11 Understanding the aesthetic concerns and psychological well-being unique to the transgender population is important for providing optimal patient care. 12 Transgender patients may experience "gender dysphoria" or distress about their assigned sex at birth. 12 Inclusive and compassionate patient communication is key when working with transgender patients and managing treatment expectations.…”

“… 12 Transgender patients may experience “gender dysphoria” or distress about their assigned sex at birth. 12 Inclusive and compassionate patient communication is key when working with transgender patients and managing treatment expectations. Clinicians should also realize that communication may differ between transgender and cisgender male/female patients.…”

Porphyria cutanea tarda unmasked by supratherapeutic estrogen during gender-affirming hormone therapy

“…1 Gender-affirming hormone therapy (HT) provides several desired physical and physiologic changes and can reduce suicidal ideation by nearly one half 2 ; however, it can also induce unwanted dermatologic side effects. 3 A growing body of literature is emerging to define these effects and their management, which commonly include acne, changes in hair distribution or density, and hyperpigmentation. 3,4 An increased susceptibility to female predominant autoimmune conditions has also been suggested, 5 raising concern that transgender females on long-term HT may additionally be at risk for other conditions commonly linked to estrogen exposure, such as porphyria cutanea tarda (PCT), erythema nodosum, vascular lesions, and cutaneous manifestations of changes in bile or lipid metabolism.…”

“…3 A growing body of literature is emerging to define these effects and their management, which commonly include acne, changes in hair distribution or density, and hyperpigmentation. 3,4 An increased susceptibility to female predominant autoimmune conditions has also been suggested, 5 raising concern that transgender females on long-term HT may additionally be at risk for other conditions commonly linked to estrogen exposure, such as porphyria cutanea tarda (PCT), erythema nodosum, vascular lesions, and cutaneous manifestations of changes in bile or lipid metabolism. 6 We report the case of a 55-year-old woman (maleto-female transgender) who presented with PCT following a change in HT that led to supratherapeutic estrogen.…”

Quality care for lesbian, gay, bisexual, transgender, and queer patients in pediatric dermatology

“…Importantly, one factor contributing to LGBTQ health disparities, according to Healthy People 2020, is a “shortage of health care providers who are knowledgeable and culturally competent in LGBTQ health.” That shortage underscores the importance of Boos et al's two‐part review of LGBTQ health issues in this issue of Pediatric Dermatology . The review adds to an increasing focus on LGBTQ health in dermatology, including reviews, textbook chapters, and research articles; educational sessions at dermatology conferences; the creation in 2017 of an Expert Resource Group on LGBT/Sexual and Gender Minority Health within the American Academy of Dermatology (AAD); advocacy efforts to make iPLEDGE for isotretinoin and similar FDA‐mandated Risk Evaluation and Mitigation Strategies more inclusive of transgender persons, and to make dermatology education more inclusive of LGBTQ health concerns; and the AAD's adoption, in March 2019, of a position statement strongly supportive of efforts to promote LGBTQ health…”